Accès libre

EGF enema and EGFR monoclonal antibody injection alleviate the inflammatory bowel disease in AMO/DSS induced mice model

Xueyan Zheng

Xueyan Zheng

Department of Gastroenterology, First Affiliated Hospital of Fujian Medical UniversityFuzhou, China
Profil Orcid
Recherchez cet auteur sur
Sciendo|Google Scholar
Zheng, Xueyan
 et 
Chengdang Wang

Chengdang Wang

Department of Gastroenterology, First Affiliated Hospital of Fujian Medical UniversityFuzhou, China
Profil Orcid
Recherchez cet auteur sur
Sciendo|Google Scholar
Wang, Chengdang
  
21 juin 2025
EGF enema and EGFR monoclonal antibody injection alleviate the inflammatory bowel disease in AMO/DSS induced mice model's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Télécharger la couverture
Catégorie d'article: Original Study
Publié en ligne: 21 juin 2025
Pages: 87 - 94
Reçu: 19 sept. 2024
Accepté: 12 mai 2025
DOI: https://doi.org/10.2478/ahem-2025-0011
Mots clés
© 2025 Xueyan Zheng et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1.

The effect of EGFR mAb treatment combined with EGF enema in the IBD model in vivo. (A) Line-graph showing changes in body weight of mice (n=3 per group) in control, AOM/DSS model, model with EGF enema and model with EGF enema and EGFR mAb treatment. Treatment time and cycles are mentioned. (B) Bar-graph showing changes in weight of colon tissues (grams) among control, AOM/DSS model, model with EGF enema and model with EGF enema and EGFR mAb treatment. Data is presented as mean ± SEM. * indicates comparison to the initial body weight (Week 0), and # denotes comparison to the body weight at Week 2. ns; non-significant. *P<0.05, **P<0.01, ***P<0.001, # P<0.05, ##P<0.01, ###P<0.001
The effect of EGFR mAb treatment combined with EGF enema in the IBD model in vivo. (A) Line-graph showing changes in body weight of mice (n=3 per group) in control, AOM/DSS model, model with EGF enema and model with EGF enema and EGFR mAb treatment. Treatment time and cycles are mentioned. (B) Bar-graph showing changes in weight of colon tissues (grams) among control, AOM/DSS model, model with EGF enema and model with EGF enema and EGFR mAb treatment. Data is presented as mean ± SEM. * indicates comparison to the initial body weight (Week 0), and # denotes comparison to the body weight at Week 2. ns; non-significant. *P<0.05, **P<0.01, ***P<0.001, # P<0.05, ##P<0.01, ###P<0.001

Figure 2.

EGFR mAb treatment combined with EGF enema alleviates colonic inflammation in the IBD model in vivo. (A-D) Representative H&E staining images (100x) of colon tissue from control (A), AOM/DSS model (B), model with EGF enema (C) and model with EGF enema and EGFR mAb treatment (D)
EGFR mAb treatment combined with EGF enema alleviates colonic inflammation in the IBD model in vivo. (A-D) Representative H&E staining images (100x) of colon tissue from control (A), AOM/DSS model (B), model with EGF enema (C) and model with EGF enema and EGFR mAb treatment (D)

Figure 3.

EGFR mAb treatment combined with EGF enema reduces proliferation in the IBD model in vivo. (A) IHC images (100x) showing changes in expression of Ki67 and EGFR among control, AOM/DSS model, model with EGF enema and model with EGF enema and EGFR mAb treatment. (B) Bar-graph showing quantification of staining in (A). Data is presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001
EGFR mAb treatment combined with EGF enema reduces proliferation in the IBD model in vivo. (A) IHC images (100x) showing changes in expression of Ki67 and EGFR among control, AOM/DSS model, model with EGF enema and model with EGF enema and EGFR mAb treatment. (B) Bar-graph showing quantification of staining in (A). Data is presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001

Figure 4.

EGFR mAb treatment combined with EGF enema reduces oncogenic signaling in the IBD model in vivo. (A) Immunoblots showing changes in expression of p-AKT, p-ERK and EGFR among control, AOM/DSS model, model with EGF enema and model with EGF enema and EGFR mAb treatment. (B) Bar-graph showing quantification of changes in protein expression in (A). Data is presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001
EGFR mAb treatment combined with EGF enema reduces oncogenic signaling in the IBD model in vivo. (A) Immunoblots showing changes in expression of p-AKT, p-ERK and EGFR among control, AOM/DSS model, model with EGF enema and model with EGF enema and EGFR mAb treatment. (B) Bar-graph showing quantification of changes in protein expression in (A). Data is presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001
Langue:
Anglais
Périodicité:
1 fois par an
Sujets de la revue:
Sciences de la vie, Biologie moléculaire, Microbiologie et virologie, Médecine, Sciences médicales de base, Immunologie
RSS Feed de la revue